The latest headlines across every section, pulled from official and open-access sources.
As Neuphoria continues to navigate the fallout of its failed social anxiety program, the biotech is mulling an offer from another potential buyer.
Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist’s market share with its own next-gen platform.
United Therapeutics has been given a premarket approval from the FDA for its LungFX device.
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The company has yet to share data from a third trial that missed its primary endpoint.
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
Background: Whether sedative prescriptions after hospital admissions are associated with poor patient outcomes is unknown. We sought to determine the incidence and risk of adverse events associated with sedatives in older adults within 30 days after hospital discharge. Methods: We conducted a population-based cohort study involving older adults (age ≥ 66 yr) discharged alive from hospital in Ontario (2003 to 2023). We assessed the association of sedative prescriptions (benzodiazepines, antidepressant sedatives, or antipsychotics) filled within 7 days after discharge with falls (with or…
In the Original Investigation titled “Pharmacologic Thromboprophylaxis in Medical Inpatients: A Systematic Review and Network Meta-Analysis,” published May 15, 2026, Laura Girardi’s academic degree was incorrectly listed as PhD instead of MD in the author byline. This article has been corrected.
The Original Investigation titled “Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders,” published on May 8, 2026, was corrected to fix wording in the Abstract Results, which now states that women with PMD were twice as likely as women without PMD to receive a subsequent psychiatric disorder diagnosis. This article was corrected online.
Emergency Medicine
Infectious Diseases
This cross-sectional study assesses the prevalence and associated characteristics of registered studies related to suicidal thoughts and behaviors that have been discontinued.
This cohort study examines the association of cardiovascular health during pregnancy, assessed using a modified Life’s Essential 8 score, with time to incident cardiometabolic disease.
This cohort study evaluates the incidence of and factors associated with hospital readmission and late mortality after discharge among children undergoing surgical repair of congenital diaphragmatic hernia.
This cohort study characterizes treatment patterns and attrition rates in a contemporary dataset of patients with metastatic castration-resistant prostate cancer to understand how these therapies are used in clinical practice.
This cross-sectional study of children aged 2 weeks through 10 years estimates optimal and reference threshold curves for pediatric hemoglobin levels, expressed as a continuous function of age.
This diagnostic study compares the ability of 6 different large language models (LLMs) to identify missed opportunities for diagnosis among patients admitted to emergency departments (EDs) that use electronic trigger (eTrigger) tools for quality and safety surveillance.
This cohort study examines whether adoption of statewide cost-growth benchmark programs is associated with changes in per capita total medical expenditures growth.
This cohort study reports a secondary analysis of the BALANCE randomized clinical trial assessing whether procalcitonin levels are associated with survival among patients receiving 7 vs 14 days of antibiotics for bloodstream infections.
Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to Tepezza, an Amgen drug that had been the only approved therapy for this inflammatory eye disorder. The post FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med appeared first on MedCity News .
CMS is recalculating some 2026 Medicare Advantage Star Ratings after a court ruled it improperly calculated Clover Health’s rating, a decision that could boost payments for a small number of insurers. The post CMS Recalculates Star Ratings — Again appeared first on MedCity News .